MDT

87.92

-0.94%↓

A

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

A

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

A

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

A

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

A

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

Search

Stryker Corp

Închisă

SectorSănătate

338.74 -0.31

Rezumat

Modificarea prețului

24h

Curent

Minim

333.42

Maxim

340.02

Indicatori cheie

By Trading Economics

Venit

-10M

849M

Vânzări

1.1B

7.2B

P/E

Medie Sector

39.607

66.418

EPS

4.47

Randament dividend

1.03

Marjă de profit

11.839

Angajați

56,000

EBITDA

351M

1.7B

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+25.49% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

1.03%

2.36%

Următoarele câștiguri

30 apr. 2026

Data viitoare de dividende

30 apr. 2026

Următoarea dată ex-dividende

29 iun. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-9.3B

127B

Deschiderea anterioară

339.05

Închiderea anterioară

338.74

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

Stryker Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

12 mar. 2026, 21:42 UTC

Evenimente importante

Stryker Says Cyberattack Disruption Is Continuing

11 mar. 2026, 19:18 UTC

Principalele dinamici ale pieței

Stryker Shares Down After Cyberattack Tied to Iran-Linked Group

29 ian. 2026, 22:05 UTC

Câștiguri

Stryker Logs Higher 4Q Profit On Sales Gains

30 oct. 2025, 20:36 UTC

Câștiguri

Stryker Lifts Fiscal Year Sales View After 3Q Revenue Rises

31 iul. 2025, 20:42 UTC

Câștiguri

Stryker Lifts Guidance on Improving Tariff Outlook

9 apr. 2026, 20:55 UTC

Câștiguri

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

9 apr. 2026, 20:55 UTC

Câștiguri

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

9 apr. 2026, 20:55 UTC

Câștiguri

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

16 mar. 2026, 00:00 UTC

Evenimente importante

Hack on U.S. Medical Company Shows Reach of Iran's Cyber Capabilities -- WSJ

30 ian. 2026, 17:03 UTC

Market Talk

Stryker's 4Q Results Signal 2026 Growth -- Market Talk

29 ian. 2026, 21:07 UTC

Câștiguri

Stryker Sees 2026 Organic Net Sales Growth 8%-9.5%

29 ian. 2026, 21:05 UTC

Câștiguri

Stryker 4Q Adj EPS $4.47 >SYK

5 nov. 2025, 19:38 UTC

Câștiguri

This Healthcare Stock Is the Worst Performer in the S&P 500 Today. Here's Why. -- Barrons.com

5 nov. 2025, 17:00 UTC

Câștiguri

This Healthcare Stock Is Worst Performer in the S&P 500 Today. Here's Why. -- Barrons.com

30 oct. 2025, 20:21 UTC

Câștiguri

Stryker Lifts FY Sales View After 3Q Revenue Rises

30 oct. 2025, 20:05 UTC

Câștiguri

Stryker 3Q Adj EPS $3.19 >SYK

30 oct. 2025, 20:05 UTC

Câștiguri

Stryker 3Q EPS $2.22 >SYK

30 oct. 2025, 20:05 UTC

Câștiguri

Stryker 3Q Sales $6.1B >SYK

30 oct. 2025, 20:05 UTC

Câștiguri

Stryker 3Q Net $859M >SYK

30 oct. 2025, 20:05 UTC

Câștiguri

Stryker Sees FY Adj EPS $13.50-Adj EPS $13.60 >SYK

30 oct. 2025, 20:05 UTC

Câștiguri

Stryker 3Q Adj EPS $3.19 >SYK

30 oct. 2025, 20:05 UTC

Câștiguri

Stryker 3Q Net $859M >SYK

30 oct. 2025, 20:05 UTC

Câștiguri

Stryker 3Q Sales $6.06B >SYK

30 oct. 2025, 20:05 UTC

Câștiguri

Stryker 3Q EPS $2.22 >SYK

31 iul. 2025, 20:09 UTC

Câștiguri

Stryker Estimates Net Impact From Tariffs in 2025 of Approximately $175M

31 iul. 2025, 20:09 UTC

Câștiguri

Stryker Sales >SYK

31 iul. 2025, 20:09 UTC

Câștiguri

Stryker Sees FY25 Organic Net Sales Up 9.5%-10%

31 iul. 2025, 20:05 UTC

Câștiguri

Stryker 2Q Sales $6B >SYK

31 iul. 2025, 20:05 UTC

Câștiguri

Stryker 2Q Net $884M >SYK

31 iul. 2025, 20:05 UTC

Câștiguri

Stryker Sees FY Adj EPS $13.40-Adj EPS $13.60 >SYK

Comparație

Modificare preț

Stryker Corp Așteptări

Obiectiv de preț

By TipRanks

25.49% sus

Prognoză pe 12 luni

Medie 426.68 USD  25.49%

Maxim 469 USD

Minim 357 USD

În baza a 21 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruStryker Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

21 ratings

17

Cumpărare

4

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

373.92 / 383.99Suport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Bullish Evidence

Termen lung

Bullish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Stryker Corp

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
help-icon Live chat